A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug known
as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive
participants with radiographic axial spondyloarthritis (rad-axSpA).